Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 5
Submit an article Journal homepage
273
Views
61
CrossRef citations to date
0
Altmetric
Review

Yeast whole glucan particle (WGP) β-glucan in conjunction with antitumour monoclonal antibodies to treat cancer

Jun YanJames Graham Brown Cancer Center Tumour Immunobiology Program, University of Louisville, 580 S. Preston Street, Louisville, KY 40202USATel: +1 502 852 3628; Fax: +1 502 852 2123;E-mail: [email protected]
,
Daniel J Allendorf Tel: +1 502 852 5357; Fax: +1 502 852 2123;E-mail: [email protected]
&
Brian Brandley Tel: +1 651 256 4620; Fax: +1 651 675 0400;E-mail: [email protected]
Pages 691-702 | Published online: 24 Nov 2005

Bibliography

  • PARDOLL D, ALLISON J: Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med. (2004) 10(9):887–892.
  • ROBBINS PF, EL-GAMIL M, LI YF et al.: Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J. Immunol. (2002) 169(10):6036–6047.
  • CORDON-CARDO C, FUKS Z, DROBNJAK M et al.: Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. (1991) 51(23 Pt 0:6372–6380.
  • GARRIDO F, CABRERA T, CONCHA A et al.: Natural history of HLA expression during tumour development. Immunol Today (1993) 14(10):491–499.
  • LEYLAND-JONES B: Trastuzumab: hopes and realities. Lancet Oncol (2002) 3(3):137–144.
  • RANSON M, SLIWKOWSKI MX: Perspectives on anti-HER monoclonal antibodies. Oncology (2002) 63\(Suppl. 1):17–24.
  • PLOSKER GL, FIGGITT DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs (2003) 63(8):803–843.
  • ROSS JS, SCHENKEIN DP, PIETRUSKO R et al: Targeted therapies for cancer 2004. Am. J. Clin. Pathol (2004) 122(4):598–609.
  • GELDERMAN KA, TOMLINSON S, ROSS GD, GORTER A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol (2004) 25(3):158–164.
  • JOHNSON P, GLENNIE M: The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol (2003) 30(1 Suppl. 2):3–8.
  • MILENIC DE, BRECHBIEL MW: Targeting of radio-isotopes for cancer therapy. Cancer Biol. Ther. (2004) 3(4):361–370.
  • ZHANG H, RICHTER M, GREENE MI: Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol. Ther. (2003) 2(4 Suppl. 1):5122–5126.
  • BASELGA J, GIANNI L, GEYER C et al: Future options with trastuzumab for primary systemic and adjuvant therapy. Semin. Oncol. (2004) 31(5 Suppl. 10):51–57.
  • TANABE H, IMAI N, TAKECHI K: [Studies on usefulness of postoperative adjuvant chemotherapy with lentinan in patients with gastrointestinal cancer]. Nippon Gan Chiryo Gakkai Shi (1990) 25(8):1657–1667.
  • KIMURA Y, TOJIMA H, FUKASE S, TAKEDA K: Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Otolaryngol. Suppl. (1994) 511:192–195.
  • MATSUOKA H, SEO Y, WAKASUGI H, SAITO T, TOMODA H: Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. (1997) 17(4A):2751–2755.
  • DI LUZIO NR, WILLIAMS DL, MCNAMEE RB, EDWARDS BF, KITAHAMA A: Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan. Int. J. Cancer (1979) 24(6):773–779.
  • HUNTER JT, MELTZER MS, RIBI E et al: Glucan: attempts to demonstrate therapeutic activity against five syngeneic tumors in guinea pigs and mice. J. Natl Cancer Inst. (1978) 60(2):419–424.
  • ROSS GD, CAIN JA, MYONES BL, NEWMAN SL, LACHMANN PJ: Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 4(2):61–74.
  • ••Results suggest the role of CR3 inparticulate 0-glucan-mediated responses. Neutrophil ingestion of yeast-derived particulate glucan or neutrophil superoxide burst was blocked by anti-CR3 mAb. The superoxide burst response to 13-glucan particles was completely absent with neutrophils from patients with an inherited deficiency of CR3.
  • THORNTON BP, VETVICKA V, PITMAN M, GOLDMAN RC, ROSS GD: Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD1 1 b/CD 1 8).j Immunol (1996) 156(3):1235–1246.
  • ••Results show that CR3 (Mac-1, CD11b/CD18) served as the 13-glucan receptor through lectin sites.
  • VETVICKA V, THORNTON BP, ROSS GD: Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. (1996) 98(1):50–61. Results suggest that soluble 13-glucan induced a primed state of CR3 that could trigger the killing of iC3b-target cells that were otherwise resistant to cytotoxicity in vitro.
  • YAN J, VETVICKA V, XIA Y et ell.: Beta-glucan, a 'specific' biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol (1999) 163(6):3045–3052.
  • ••Results suggest that 0-glucan-mediatedtumour therapy requires both iC3b deposition on tumour cells mediated by natural antibodies and polysaccharide fl-glucan. The requirement for C3 on tumours and CR3 on leukocytes was highlighted by therapy failures in C3- or CR3-deficient mice.
  • XIA Y, ROSS GD: Generation of recombinant fragments of CD1 lb expressing the functional beta-glucan-binding lectin site of CR3 (CD1 lb/CD18). Immunol (1999) 162(12):7285–7293.
  • •Recombinant CD11b was generated to further characterise the fl-glucan binding site.
  • XIA Y, VETVICKA V, YAN J et al: The beta-glucan-binding lectin site of mouse CR3 (CD1 lb/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Immunol (1999) 162(4):2281–2290.
  • WASSER SP, WEIS AL: Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit. Rev. Immunol (1999) 19(1):65–96.
  • GAWRONSKI M, PARK JT, MAGEE AS, CONRAD H: Microfibrillar structure of PGG-glucan in aqueous solution as triple-helix aggregates by small angle X-ray scattering. Biopolymers (1999) 50(6):569–578.
  • -WILLIAMS DL, PRETUS HA, MCNAMEE RB et al: Development, physicochemical characterization and preclinical efficacy evaluation of a water soluble glucan sulfate derived from Saccharomyces cerevisiae. Immunopharmacology (1991) 22(3):139–155.
  • •Characterisation of soluble yeast 3-glucan.
  • ENSLEY HE, TOBIAS B, PRETUS HA et al.: NMR spectral analysis of a water-insoluble (1- 3)-beta-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr. Res. (1994) 258:307–311.
  • OSUMI M: The ultrastructure of yeast: cell wall structure and formation. Micron (1998) 29(2-3):207–233.
  • CASSONE A. BISTONI F, CENCI E et al.: Immunopotentiation of anticancer chemotherapy by Candida albicans, other yeasts and insoluble glucan in an experimental lymphoma model. Sabouraudia (1982) 20(2):115–125.
  • WILLIAMS DL, MCNAMEE RB, JONES EL et al.: A method for the solubilization of a (1-3)-beta-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr. Res. (1991) 219:203–213.
  • BABINEAU TJ, MARCELLO P, SWAILS Wet al.: Randomized Phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. (1994) 220(5):601–609.
  • BABINEAU TJ, HACKFORD A, KENLER A et al.: A Phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. (1994) 129(10:1204–1210.
  • TZIANABOS AO, CISNEROS RL: Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann. IVY Acad. Sci. (1996) 797:285–287.
  • LIANG J, MELICAN D, CAFRO L et cd: Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Immunopharmacol (1998) 20(11):595–614.
  • PATCHEN ML, VAUDRAIN T, CORREIRA H, MARTIN T, REESE D: In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp. Hematol (1998) 26(13):1247–1254.
  • REICHNER JS, FITZPATRICK PA, WAKSHULL E, ALBINA JE: Receptor-mediated phagocytosis of rat macrophages is regulated differentially for opsonized particles and non-opsonized particles containing beta-glucan. Immunology (2001) 104(2):198–206.
  • MARKIEWICZ MA, KAST WM: Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. (2004) 22(3):417–434.
  • NIEHANS GA, CHERWITZ DL, STALEY NA, KNAPP DJ, DALMASSO AP: Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. PathoL (1996) 149(1):129–142.
  • VARSANO S, FROLKIS I, RASHKOVSKY L, OPHIR D, FISHELSON Z: Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. Am. J. Respir. Cell Md. Biol. (1996) 15(6):731–737.
  • LI L, SPENDLOVE I, MORGAN J, DURRANT LG: CD55 is over-expressed in the tumour environment. Br. J. Cancer (2001) 84(1):80–86.
  • ROSS GD: Regulation of the adhesion versus cytotoxic functions of the Mac-1/ CR3/alphaMbeta2-integrin glycoprotein. Crit. Rev. Immunol (2000) 20(3):197–222.
  • KLEIN E, DI RENZO L, YEFENOF E: Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. Mol Immunol (1990) 27(12):1343–1347.
  • ROSS GD, VETVICKA V: CR3 (CD11 b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin. Exp. Immunol (1993) 92(2):181–184.
  • HONG F, HANSEN RD, YAN J et al.: Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. (2003) 63(24):9023–9031.
  • ••Five mouse syngeneic tumour models wereused to test the efficacy of combined soluble yeast 3-glucan in combination with antitumour mAbs.
  • HONG F, YAN J, BARAN JT et cll.: Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol (2004) 173(2):797–806.
  • ••Cellular and molecular mechanisms ofaction have been demonstrated for combined oral-administered 3-glucan with antitumour mAbs.
  • YAN J, VETVICKA V, XIA Y et al: Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology (2000) 46(1):39–54.
  • •Results suggest that soluble 3-glucan exhibited rapid clearance to the liver in normal mice, whereas clearance in CR3-K0 mice was significantly reduced.
  • BROWN GD, HERRE J, WILLIAMS DL et al: Dectin-1 mediates the biological effects of beta-glucans J. Exp. Med. (2003) 197(9):1119–1124.
  • •The experimental data demonstrate that TNF-a secretion by macrophages was dependent on Toll-like receptor 2 (TLR2), MyD88 and Dectin-1. This finding was novel in that TLR2 alone was not sufficient to mediate cytokine expression, and suggested that Dectin-1 may have a role in innate immunity as a pattern-recognition receptor of non-opsonised ll-glucans.
  • TAYLOR PR, BROWN GD, REID DM et al: The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol (2002) 169(7):3876–3882.
  • VETVICKA V, THORNTON BP, WIEMAN TJ, ROSS GD: Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). J. Immunol. (1997) 159(2):599–605.
  • ••In vitro experiments demonstrated that priming of NK cell CR3 with small soluble yeast 3-glucan enabled the killing of iC3b-opsonised tumour cell lines and mammary carcinoma cells from freshly excised tumours.
  • ROBERTSON MJ, RITZ J: Biology andclinical relevance of human natural killer cells. Blood (1990) 76(12):2421–2438.
  • PAPAMICHAIL M, PEREZ SA, GRITZAPIS AD, BAXEVANIS CN: Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother. (2004) 53(3):176–186.
  • EHRENGRUBER MU, GEISER T, DERANLEAU DA: Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett. (1994) 346(2-3):181–184.
  • JAGELS MA, CHAMBERS JD, ARFORS KE, HUGLI TE: C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood (1995) 85(10):2900–2909.
  • PETERING H, KOHL J, WEYERGRAF A et al.: Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a. j Immunol (2000) 164(7):3783–3789.
  • ZWIRNER J, GOTZE 0, BEGEMANN G et al: Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology (1999) 97(1):166–172.
  • EMBER JA, HUGLI TE: Complement factors and their receptors. Immunopharmacology (1997) 38(1-2):3–15.
  • HARIBABU B, VERGHESE MW, STEEBER DA et al: Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J. E. Med. (2000) 192(3):433–438.
  • NANBA H, KURODA H: Antitumor mechanisms of orally administered shiitake fruit bodies. Chem. Pharm. Bull. (Tokyo) (1987) 35(6):2459–2464.
  • SUZUKI I, SAKURAI T, HASHIMOTO K et al.: Inhibition of experimental pulmonary metastasis of Lewis lung carcinoma by orally administered beta-glucan in mice. Chem. Pharm. Bull. (Tokyo) (1991) 39(6):1606–1608.
  • CHEUNG NK, MODAK S: Oral (1-> 3),(1- 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. (2002) 8(5):1217–1223.
  • ••In vivo human neuroblastoma xenograftathymic nude mouse model demonstrated the therapeutic efficacy of combining barley 13-glucan with anti-GD2 mAb 3F8.
  • CHEUNG NK, MODAK S, VICKERS A. KNUCKLES B: Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. (2002) 51(10):557–564.
  • KO EC, WANG X, FERRONE S: Immunotherapy of malignant diseases. Challenges and strategies. Int. Arch. Allergy Immunol (2003) 132(4):294–309.
  • ROSS GD, VETVICKA V, YAN J, XIA Y,VETVICKOVA J: Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology (1999) 42(1-3):61–74.
  • SIER CF, GELDERMAN KA, PRINS FA, GORTER A Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. Int. J. Cancer (2004) 109(6):900–908.
  • •Results suggest that13-glucan enhanced the killing of renal cell carcinoma micrometastases when used in combination with mAb.
  • FOON KA, CHAKRABORTY M, JOHN WJ et al.: Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest. (1995) 96(1):334–342.
  • KARANIKAS V HWANG LA, PEARSON J et al.: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. (1997) 100(10:2783–2792.
  • NICHOLSON S, BOMPHRAY CC, THOMAS H et al.: A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother. (2004) 53(9):809–816.
  • SPIRIDON CI, GHETIE MA, UHR J et al.: Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. (2002) 8(6):1720–1730.
  • DUTTA T, SPENCE A, LAMPSON LA:Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J. Neurooncol (2003) 64(1-2):31–44.
  • KAUFMAN HL, DISIS ML: Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. Clin. Invest. (2004) 113(5):664–667.
  • HARIBABU B, RICHARDSON RM, VERGHESE MW et al.: Function and regulation of chemoattractant receptors. Immunol. Res. (2000) 22(2-3):271–279.

Websites

  • http://cancer.gov/clinicaltrials/MSKCC-01075 The National Cancer Institute, US National Institutes of Health: Phase I Study of beta-glucan and monoclonal antibody 3F8 in patients with metastatic neuroblastoma (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.